Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 5/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 8/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13391222 | 1.00 | ACKR3 (0.42) | ACKR3PDE4BPDE11APDE10ATBK1 | |
| SCHEMBL13390965 | 1.00 | ACKR3 (0.42) | ACKR3PDE4BPDE11APDE10ATBK1 | |
| SCHEMBL13391261 | 1.00 | ACKR3 (0.42) | ACKR3PDE4BPDE11APDE10ATBK1 | |
| SCHEMBL13391202 | 1.00 | ACKR3 (0.42) | ACKR3PDE4BPDE11APDE10ATBK1 | |
| SCHEMBL13391111 | 1.00 | ACKR3 (0.42) | ACKR3PDE4BPDE11APDE10ATBK1 | |
| SCHEMBL13409692 | 1.00 | ACKR3 (0.42) | ACKR3PDE4BPDE11APDE10ATBK1 | |
| SCHEMBL13391598 | 0.91 | ACKR3 (0.41) | ACKR3TBK1TLR9TLR8TLR7 | |
| SCHEMBL14355995 | 0.91 | ACKR3 (0.40) | ACKR3TBK1 | |
| SCHEMBL13391321 | 0.91 | ACKR3 (0.40) | ACKR3TBK1 | |
| SCHEMBL14188212 | 0.90 | ACKR3 (0.46) | ACKR3PDE4BPDE11APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | SCHERING CORPORATION SECHERING-PLOUGH CORPORATION (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2008108957-A2 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | SCHERING CORPORATION (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | SCHERING CORPORATION | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | GPR119, ATF4, GID4 | ACKR3 2293/4885PDE4B 376/4885PDE11A 1019/4885 |
| US-20080119487-A1 | NOVEL NON-IMIDAZOLE COMPOUNDS | HRH2, HRH1, HRH4 | ACKR3 67/4885PDE4B 380/4885PDE11A 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.